WJA
GLMD icon

Williams Jones & Associates’s Galmed Pharmaceuticals GLMD Stock Holding History

Williams Jones & Associates’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-10
Closed -$67K – 387
2016
Q3 		$67K Buy
10
+3
+43% +$18.1K ﹤0.01% 385
2016
Q2 		$45K Buy
+7
New +$52.9K ﹤0.01% 383

Other funds holding GLMD

6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $126M AUM 15.32% 1-Year Est. Return
MC
Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
CA
CapWealth Advisors Franklin, Tennessee $1.46B AUM 33.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Williams Jones & Associates's GLMD Position: Q4 2016 in Review

Williams Jones & Associates sold out of Galmed Pharmaceuticals (GLMD) in Q4 2016, closing a stake of 10 shares — an estimated $67K sold.

Williams Jones & Associates first reported a position in GLMD in Q2 2016 and held it in 2 quarters. The position peaked at $67K in Q3 2016. 10 funds tracked by Wall St. Rank hold GLMD as of Q4 2016.

  • Williams Jones & Associates reported no remaining Galmed Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Williams Jones & Associates sold 10 Galmed Pharmaceuticals shares in Q4 2016, an estimated $67K.
  • Williams Jones & Associates first reported a position in Galmed Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • Williams Jones & Associates's Galmed Pharmaceuticals position peaked at $67K in Q3 2016.
  • 10 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2016.

Based on Williams Jones & Associates's 13F filing for Q4 2016, filed 14 Feb 2017.